Study identifier:D1449L00023
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
The Effect of the Atypical Antipsychotic Quetiapine in the Treatment of Postpartum Depressive Disorder with Psychotic Symptoms
Postpartum Depressive Disorder
Phase 2
No
Quetiapine
Female
5
Interventional
18 Years - 39 Years
Allocation: N/A
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Dec 2010 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Quetiapine Fumarate 150 - 800mg Quetiapine 150-800mg | Drug: Quetiapine 150-800 mg, oral, twice a day (bid) Other Name: Seroquel |